electroCore (NASDAQ:ECOR) Issues Quarterly Earnings Results

electroCore (NASDAQ:ECOR) announced its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.14, FiscalAI reports. The company had revenue of $9.69 million for the quarter, compared to the consensus estimate of $10.93 million.

Here are the key takeaways from electroCore’s conference call:

• electroCore reported record third-quarter net sales of $9.7 million, up 12% year over year, with gross margin expanding to 88.5%. Adjusted EBITDA loss narrowed to a company-low $700,000, although GAAP results included a $400,000 settlement gain and a $100,000 tax benefit.
• The company lowered its 2026 revenue outlook to $39 million–$42 million, saying sales-force changes delayed the acceleration it had expected in the second half. Management now anticipates 30%–40% revenue growth in 2027 and targets its first positive Adjusted EBITDA quarter by year-end 2027, both dependent on execution.
• Management cited early gains from its commercial overhaul: newer representatives generated about 30% more monthly VA revenue than the territories did before, and VA new-patient orders rose 21% year over year. Refill revenue reached a company high, while the national refill rate was 42% through September, below the company’s goal of more than 70%.
• electroCore filed an FDA 510(k) submission for Quell to treat chemotherapy-induced peripheral neuropathy (CIPN), a potential new market that management estimates at 600,000–700,000 U.S. patients. Clearance and any resulting sales remain uncertain; the company said CIPN-specific revenue is not included in its 2027 growth outlook.
• Cash, cash equivalents, and marketable securities fell to $7.5 million from $10 million at the end of the prior quarter. The company is evaluating a term-loan refinancing to support its runway, but said it has no agreement in place.

electroCore Price Performance

ECOR traded up $1.17 during trading on Wednesday, hitting $8.40. 235,534 shares of the stock traded hands, compared to its average volume of 79,272. The firm has a market capitalization of $75.77 million, a P/E ratio of -5.06 and a beta of 1.23. electroCore has a 12-month low of $4.41 and a 12-month high of $12.70. The firm has a 50-day moving average of $9.36 and a 200 day moving average of $7.75.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of electroCore in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $18.00.

Insider Transactions at electroCore

In other news, CFO Joshua Lev sold 12,000 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $10.22, for a total transaction of $122,640.00. Following the completion of the transaction, the chief financial officer directly owned 84,889 shares of the company’s stock, valued at approximately $867,565.58. This represents a 12.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Thomas J. Errico bought 5,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were purchased at an average price of $9.85 per share, with a total value of $49,250.00. Following the completion of the acquisition, the director owned 343,332 shares of the company’s stock, valued at $3,381,820.20. This trade represents a 1.48% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 20,000 shares of company stock worth $200,120 in the last 90 days. Corporate insiders own 7.80% of the company’s stock.

About electroCore

electroCore, Inc (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.

The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.